GPX4, Ferroptosis, and a New Generation of Senolytics: Killing Senescent Cells via Metabolic Vulnerabilities

1. Introduction: A Second Death Pathway for Senescent Cells

Senescent cells — cells that have permanently exited the cell cycle but remain metabolically active — accumulate with age and secrete a cocktail of inflammatory and matrix-remodelling factors known as the senescence-associated secretory phenotype (SASP). Because they contribute to tissue dysfunction, clearing them is among the most actively pursued strategies in aging research. First-generation senolytics such as dasatinib plus quercetin, fisetin, and navitoclax work mainly by disabling the anti-apoptotic defences of senescent cells, forcing them into apoptosis.

Apoptosis, however, is only one form of programmed cell death. In 2012 a distinct, iron-dependent death modality was described and named ferroptosis: the peroxidation of membrane phospholipids to the point of membrane rupture. Because it is mechanistically independent of apoptosis, ferroptosis offers a parallel route to kill cells that resist conventional senolytics, and it has become a candidate framework for a «second generation» of senolytic drugs.

This article explains the biology of ferroptosis, the central role of the enzyme glutathione peroxidase 4 (GPX4), the relationship between senescence and ferroptosis (which is more complex and more contested than often presented), and the state of the drug pipeline. As elsewhere in this section, claims are labelled established, emerging, hypothesis, or speculative.

2. Ferroptosis Biology and the GPX4 Bottleneck

2.1. Lipid Peroxidation and Labile Iron

Cell membranes contain polyunsaturated fatty acids (PUFAs), whose carbon-hydrogen bonds are susceptible to oxidative attack. Two enzyme families facilitate this: ACSL4 and LPCAT3 incorporate PUFAs into membrane phospholipids, and lipoxygenases can oxidize them. The resulting lipid peroxides, if not reduced, propagate chain reactions that destroy membrane integrity. Iron amplifies the process: labile ferrous iron (Fe²⁺) participates in Fenton chemistry to generate highly reactive hydroxyl radicals. This is why ferroptosis is specifically iron-dependent and why iron chelators block it. Evidence: established mechanism.

2.2. GPX4 and the Antioxidant Defences It Anchors

Cells continuously detoxify lipid peroxides. The principal enzymatic defence is GPX4, which uses glutathione as a cofactor to reduce lipid hydroperoxides to harmless alcohols. GPX4 depends on glutathione availability, which in turn depends on cystine import via the system x_c^— transporter (SLC7A11). Blocking GPX4, or starving cells of cystine, causes lipid peroxides to accumulate and triggers ferroptotic death within hours.

A second, GPX4-independent defence exists: the FSP1-coenzyme Q10 system, which regenerates reduced coenzyme Q10 to terminate lipid radical chains. That two parallel systems protect against ferroptosis is important, because it means that inhibiting GPX4 alone may not be sufficient in all cells, and that the efficacy of any ferroptosis-based strategy depends on which defences a target cell relies on.

The therapeutic difficulty is that GPX4 is not dispensable in normal tissue: its loss is lethal in developing brain and kidney in mice. A ferroptosis-based senolytic therefore cannot simply poison GPX4 systemically; it must achieve selectivity for senescent cells.

2.3. Are Senescent Cells Primed for Ferroptosis? A Contested Question

The intuitive model — that senescent cells accumulate iron and oxidized lipids and are held back only by upregulated GPX4, making them «primed» for ferroptosis — is partially supported but has important exceptions, and the literature is genuinely mixed.

Supporting the model: senescent cells do accumulate labile iron and lipid peroxidation products, and several groups have shown that GPX4 inhibition or ferroptosis inducers can selectively kill senescent cells across multiple cell types and senescence inducers. A 2021 study reported that senescent tubular cells can be eliminated by inducing ferroptosis, and a 2026 screen of electrophilic compounds identified GPX4 as a target whose inhibition selectively kills senescent cells by ferroptosis, including in anticancer-therapy-treated tumour models. A related 2024 study found that senescent cells upregulate GPX4 to survive and that manipulating PUFA desaturation can convert the senescence decision into ferroptosis.

Complicating the model: other work has found that senescent cells are actually more resistant to ferroptosis inducers than proliferating cells, and that this resistance arises because excess iron is sequestered inside lysosomes via ferritinophagy, with ferritin binding labile iron and protecting against Fenton chemistry. In such systems, disrupting lysosomal function — not inhibiting GPX4 — is what sensitizes senescent cells to ferroptosis.

The reconciliation is likely that the vulnerability is cell-type- and context-dependent, and that the relevant defence differs by senescence model. This matters practically: a ferroptosis senolytic that works in one tissue or senescence inducer may fail in another. Evidence: emerging and unresolved.

3. First-Generation Senolytics and Their Limits

The senolytic field rests on the demonstration that killing senescent cells in aged animals restores function in multiple tissues — joints, lung, kidney, and vasculature — which is established in mice. Drugs such as dasatinib plus quercetin (D+Q), fisetin, and navitoclax have shown benefit in animal models of age-related disease, and several small human trials have reported signals in specific indications (for example, idiopathic pulmonary fibrosis, diabetic kidney disease, and osteoarthritis). Human data remain emerging and limited: trials are small, endpoints vary, and no senolytic is approved for an aging indication. Navitoclax has haematological toxicity, and D+Q’s specificity and potency are modest.

These agents also depend on apoptosis being available. Some senescent cells — including certain paracrine-senescent cells and some therapy-resistant cancer cells — resist apoptosis, which is exactly the gap a ferroptosis-based approach is intended to fill.

4. From Tool Compounds to Therapeutics

4.1. GPX4 Inhibitors

The first GPX4 inhibitors — RSL3 and ML162 — proved the principle but lack drug-like properties, and RSL3 is not consistently selective for senescent cells. FIN56 depletes both GPX4 and coenzyme Q10 and has shown better selectivity in several senescence models. The central challenge remains delivery: because systemic GPX4 inhibition is toxic, current efforts focus on senescence-targeted prodrugs, antibody-drug conjugates, and cell-selective activation. Evidence: preclinical.

4.2. Exploiting Iron Rather Than Blocking GPX4

An alternative strategy exploits the aberrant iron handling of senescent cells directly, without global GPX4 blockade. One approach uses an iron-activatable prodrug: a molecule that is inert until it encounters labile Fe²⁺, at which point it releases a cytotoxic payload. Because senescent cells often have elevated labile iron, such a prodrug can preferentially kill them while sparing cells with normal iron levels. A 2023 study showed that ferroptosis inducers and Fe²⁺-activated prodrugs could ablate multiple types of primary and paracrine senescent cells in vitro. Evidence: preclinical; in vivo anti-aging testing still limited.

4.3. Lipid and Natural-Product Senolytics

A growing class of compounds promotes ferroptosis in senescent cells by acting on lipid metabolism. For example, a conjugated polyunsaturated fatty acid (alpha-eleostearic acid and its methyl ester) was identified as a senolytic that kills a broad range of senescent cells and extends healthspan in mice by engaging ACSL4, LPCAT3, and ALOX15. Other agents — the flavonoid 4,4′-dimethoxychalcone and the anti-malarial derivative dihydroartemisinin — have been reported to trigger ferroptosis in senescent cells via ferritinophagy or AMPK/mTOR signalling. These results are promising but early; the compounds remain preclinical, and their selectivity and safety in whole organisms require confirmation.

4.4. The Oncology Connection

Ferroptosis is also intensely studied in cancer, where drug-resistant and mesenchymal tumour cells are often vulnerable. This oncology pipeline is doing much of the medicinal-chemistry work — identifying selective inducers, combination strategies, and biomarkers of ferroptosis susceptibility — that the aging field can borrow. A particularly attractive concept is to induce senescence in tumour cells and then eliminate them by ferroptosis, combining two tumour-suppressive strategies. Evidence: emerging, mostly preclinical.

5. Prospects and the Safety Question

If a ferroptosis-based senolytic can be delivered selectively, it would extend the treatable range of senescence-driven disease to cells that resist apoptosis — a genuine advance. Two obstacles dominate. The first is selectivity: normal cells depend on GPX4 and iron homeostasis, so any global disruption of these systems risks toxicity, particularly in brain and kidney. The second is the biology of senescence itself: because vulnerability to ferroptosis varies by cell type and senescence inducer, a single agent is unlikely to clear all senescent cells, and combination approaches may be needed. This is why the field increasingly favours iron-activated prodrugs and lipid-targeted compounds over blunt GPX4 inhibitors.

It should be stated plainly that no GPX4-directed or ferroptosis-based senolytic has entered human trials for aging. The compelling animal and cell data describe a promising pipeline, not a therapy. Claims that ferroptosis senolytics could add decades of healthy life are speculative, and the same caution that applies to first-generation senolytics — that clearing senescent cells in mice is not equivalent to extending human healthspan — applies with equal force here.

6. Conclusion

GPX4 and ferroptosis broaden the conceptual arsenal of senolytics from a single death pathway to a diversified one, and the underlying mechanism is well defined: iron-dependent lipid peroxidation, restrained by GPX4 and the FSP1-coenzyme Q10 system. The most important scientific nuance is that senescent cells are not uniformly poised for ferroptosis — some are vulnerable, others resistant — so selectivity and context will determine which compounds work and where. The field is producing convincing preclinical results and a plausible drug pipeline, but it remains exactly that: a pipeline. Human validation does not yet exist.

Sources and Key Research Centers

1. Dixon SJ, Lemberg KM, Lamprecht MR, et al. «Ferroptosis: an iron-dependent form of nonapoptotic cell death.» Cell, 2012; 149(5): 1060-1072. DOI: 10.1016/j.cell.2012.03.042 — Discovery of ferroptosis.
2. Yang WS, SriRamaratnam R, Welsch ME, et al. «Regulation of ferroptotic cancer cell death by GPX4.» Cell, 2014; 156(1-2): 317-331. DOI: 10.1016/j.cell.2013.12.010 — GPX4 as the central ferroptosis regulator.
3. Bersuker K, Hendricks JM, Li Z, et al. «The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis.» Nature, 2019; 575(7784): 688-692. DOI: 10.1038/s41586-019-1705-2 — The GPX4-independent defence.
4. Liao CM, Wulfmeyer VC, Chen R, et al. «Induction of ferroptosis selectively eliminates senescent tubular cells.» American Journal of Transplantation, 2022; 22(9): 2158-2168. DOI: 10.1111/ajt.17102
5. Admasu TD, Kim K, Rae M, et al. «Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis.» Cell Reports, 2023; 42(2): 112058. DOI: 10.1016/j.celrep.2023.112058 — Ferroptosis inducers and Fe(II)-activated prodrugs as broad-spectrum senolytics.
6. Maus M, Lopez-Polo V, Mateo L, et al. «Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype.» Nature Metabolism, 2023; 5(12): 2111-2130. DOI: 10.1038/s42255-023-00928-2
7. PubMed: ferroptosis, senescence, and GPX4 — Index of emerging senolytic applications and reviews.
8. ClinicalTrials.gov — Registered trials of senolytic drugs (search terms: dasatinib quercetin, fisetin, senolytic). No ferroptosis-directed senolytic has entered human trials for aging.